Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.

Reuter S, Heitplatz B, Pavenstädt H, Suwelack B.

Transplantation. 2013 Nov 27;96(10):e74-6. doi: 10.1097/01.TP.0000435705.63428.1f. No abstract available.

PMID:
24247905
2.

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.

Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M.

J Med Case Rep. 2014 Sep 14;8:307. doi: 10.1186/1752-1947-8-307.

3.

Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP.

Cruzado JM, de Córdoba SR, Melilli E, Bestard O, Rama I, Sánchez-Corral P, López-Trascasa M, Navarro I, Torras J, Gomà M, Grinyó JM.

Am J Transplant. 2009 Jun;9(6):1477-83. doi: 10.1111/j.1600-6143.2009.02647.x. Epub 2009 May 20.

4.

Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab.

El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP.

Am J Kidney Dis. 2015 Jan;65(1):127-30. doi: 10.1053/j.ajkd.2014.07.031. Epub 2014 Nov 15.

PMID:
25446020
5.

Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next?

Fakhouri F, Frémeaux-Bacchi V.

Nat Rev Nephrol. 2013 Sep;9(9):495-6. doi: 10.1038/nrneph.2013.150. Epub 2013 Aug 6. No abstract available.

PMID:
23917793
6.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

7.

Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.

de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, Bay JO, Neven B, Moussi J, Simon L, Xhaard A, Resche-Riggon M, O'Meara A, Fremeaux-Bacchi V, Veyradier A, Socié G, Coppo P, de Latour RP.

Transplantation. 2015 Sep;99(9):1953-9. doi: 10.1097/TP.0000000000000601.

PMID:
25651309
8.

Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab.

Wilson CH, Brown AL, White SA, Goodship TH, Sheerin NS, Manas DM.

Transplantation. 2011 Oct 27;92(8):e42-3. doi: 10.1097/TP.0b013e318230c0bd. No abstract available.

PMID:
21989273
9.

Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report.

Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A.

Transplant Proc. 2011 Jun;43(5):2097-101. doi: 10.1016/j.transproceed.2011.02.064.

PMID:
21693335
10.

Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.

Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S, Martin PY, Villard J.

Am J Transplant. 2011 Nov;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x. Epub 2011 Aug 10.

11.

Thrombotic Microangiopathy as a Cause of Chronic Kidney Transplant Dysfunction: Case Report Demonstrating Successful Treatment with Eculizumab.

Iqbal Z, Wood K, Carter V, Goodship TH, Brown AL, Sheerin NS.

Transplant Proc. 2015 Sep;47(7):2258-61. doi: 10.1016/j.transproceed.2015.08.004.

PMID:
26361694
12.

Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism.

Frémeaux-Bacchi V, Arzouk N, Ferlicot S, Charpentier B, Snanoudj R, Dürrbach A.

Am J Transplant. 2007 Aug;7(8):2047-51.

13.

Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants.

Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M.

Am J Kidney Dis. 2012 May;59(5):707-10. doi: 10.1053/j.ajkd.2011.11.027. Epub 2011 Dec 23.

PMID:
22196848
14.

Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.

Ikeda T, Okumi M, Unagami K, Kanzawa T, Sawada A, Kawanishi K, Omoto K, Ishida H, Tanabe K.

Nephrology (Carlton). 2016 Jul;21 Suppl 1:35-40. doi: 10.1111/nep.12768.

PMID:
26970541
15.

Beneficial effect of eculizumab on thrombotic microangiopathies: another point of view.

Park SJ, Shin JI.

Am J Kidney Dis. 2014 Jan;63(1):166-7. doi: 10.1053/j.ajkd.2013.07.029. No abstract available.

PMID:
24360227
16.

Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.

Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P.

Am J Kidney Dis. 2013 Feb;61(2):289-99. doi: 10.1053/j.ajkd.2012.07.028. Epub 2012 Nov 7. Review.

PMID:
23141475
17.

In reply to 'Beneficial effect of eculizumab on thrombotic microangiopathies: another point of view'.

Schmidtko J, Peine S.

Am J Kidney Dis. 2014 Jan;63(1):167. doi: 10.1053/j.ajkd.2013.10.053. No abstract available.

PMID:
24360228
18.

Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein.

Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Frémeaux-Bacchi V, Niaudet P.

Am J Transplant. 2012 Jul;12(7):1938-44. doi: 10.1111/j.1600-6143.2012.04051.x. Epub 2012 Apr 11.

19.

Eculizumab therapy.

Cataland SR.

Biol Blood Marrow Transplant. 2014 Apr;20(4):438-9. doi: 10.1016/j.bbmt.2014.02.006. Epub 2014 Feb 15. No abstract available.

20.

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.

J Thromb Haemost. 2014 Sep;12(9):1440-8. doi: 10.1111/jth.12615. Epub 2014 Jul 16.

Supplemental Content

Support Center